Tuberculosis Pharmacogenetics: State of The Art by Teixeira, Raquel Lima de Figueiredo et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 6
Tuberculosis Pharmacogenetics: State of The Art
Raquel Lima de Figueiredo Teixeira,
Márcia Quinhones Pires Lopes,
Philip Noel Suffys and Adalberto Rezende Santos
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54984
1. Introduction
The interindividual variability in the metabolism of xenobiotics and drug response is extensive
and many factors are involved with this variation including genetic composition, gender, age,
co-administration of medication, individual physiology, pathophysiology and presence of
other environmental factors (alcohol consumption, smoking, eating habits).
To produce their therapeutic effects, the drug must be present in appropriate concentrations
at its site of action. Although the therapeutic concentrations are dependent on the given dose,
they will also depend on the magnitude and rate of absorption, distribution, biotransforma‐
tion, and excretion. Pharmacokinetics studies the course and distribution of drug and its
metabolites in different tissues, covering the mechanisms of absorption, transport, metabolism
and excretion. In addition, pharmacodynamics concentrates on the biochemical and physio‐
logical effects of drugs and their mechanism of action. Proteins involved in drug effects are
defined as target molecules and include not only (direct) receptors, but also proteins associated
with mechanism of action such as e.g. signal transducer proteins [1].
After  its  administration,  a  drug is  absorbed and then  distributed  throughout  the  body,
requiring the coordinated functioning of  various proteins,  including metabolic  enzymes,
trafficking proteins,  receptor  proteins,  and others.  Medication can enter  the  body as  ei‐
ther  active  drugs  or  as  inactive  prodrugs.  Most  drugs  are  metabolized  in  the  liver  to
make  them  more  soluble  for  subsequent  elimination  through  the  kidneys  or  intestines.
Prodrugs require  metabolic  conversion,  also  called biotransformation,  to  liberate  the  ac‐
tive  compound.  Complete  biotransformation  of  any  one  drug  typically  requires  several
different enzymes. [2].  Genetic variability has been described to have effect on drug ab‐
sorption and metabolism and its interactions with the receptors. This forms the basis for
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slow and rapid drug absorption, poor, efficient or ultrarapid drug metabolism and poor
or efficient receptor interactions [3]. The consequences of such variations can lead to ad‐
verse drug reaction and/or terapeutic failure.
In this context, pharmacogenetics is the study of genetic variations associated with individual
variability in drug response, including differences in efficacy, drug-drug interactions, and the
relative risk of an adverse response to drugs. It includes the study of genetic polymorphisms
that could affect the expression or activity of drug transporters, drug metabolizing enzymes
and drug receptors [2-4].
It’s estimated that 99.9% of the human genome sequence between individuals is identical and
genetic differences in polulations are called mutations if they are present in less than 1% and
polymorphisms when present in at least 1% of a population. A single-nucleotide polymor‐
phism (SNP) involves a replacement of one nucleotide base with any one of the other three
and occuring at approximately one out of every 1,000 bases in the human genome [5].
A mutation or polymorphism in genes that encode metabolic enzymes, carriers or receptors
can affect the drug pharmacokinetics and pharmacodinamics leading to undesired therapeutic
effects. The identification of these genetic markers which predicted if a person responds well
or not to a specific drug could help to select the right medication in right dosage, maximizing
the eficacy and preventing or reducing the adverse drug reactions.
2. Problem statement
TB is an important global public health problem but has cure in almost 100% of the new cases
if correct quimiotherapy is applied. The American Thoracic Society (ATS) treatment guidelines
recommend an initial phase for TB treatment which consists of rifampicin 10 mg/kg (maximum
600 mg), isoniazid 5 mg/kg (maximum 300 mg), pyrazinamide 15–30 mg/kg (maximum 2 g),
and ethambutol 15–20 mg/kg (maximum 1.6 g) given daily for 8 weeks, followed by a contin‐
uous phase of isoniazid 15 mg/kg (maximum 900 mg) and rifampicin 10 mg/kg (maximum 600
mg) administered 2–3 times/week for 18 weeks [6]. The use of fixed-dose combination (FDC)
tablets containing anti-TB drugs has been recommended by the World Health Organization
(WHO) as an additional measure to improve treatment adherence by reducing the number of
tablets to be taken. The principal disadvantages of combining three or more drugs in one tablet
include (a) the possibility of overdosage or underdosage resulting from a prescription error,
(b) changes in the bioavailability of rifampicin and (c) difficulties in determining which drug
is responsible for adverse effects [7].
Isoniazid (INH) is an important drug in the TB treatment and was introduced in chemo‐
therapic scheme since 1952. It is the hidrazine of isonicotinic acid and shows cytotoxic ac‐
tivity for Mycobacterium tuberculosis both in rest (during latency) and proliferation phases.
This drug enters easily in macrophague cells to kill bacilli in multiplication and is specif‐
ic for mycobacteria [1].
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INH-induced adverse reactions include fever, nausea, vomiting, hepatotoxicity, skin reactions,
gastrointestinal and neurological disorders. Only in the early 1970s, the occurrence of severe
liver injury as a side effect of this drug was recognized, resulting in the death of some patients
[8]. Among the first-line anti-TB drugs, INH is the main associated with drug-induced
hepatotocixity with a frequency ranging from 1 to 30% in different populations [9]. Other drugs
causing liver injury are mainly reported in combination with INH [10, 11]. Drug-induced
hepatotoxicity is defined as a serum alanine aminotransferase (ALT) level three times greater
than the upper limit of normal (ULN) with clinical symptoms or five times the ULN without
symptoms. In both cases treatment should be interrupted and, generally, a modified or
alternative regimen is introduced [9]. Because these adverse reactions do not only affect
morbidity and mortality rate but also lead to treatment interruptions, failure and relapse,
adverse reactions contribute to the spread of the disease and the emergence of multidrug
resistence (MDR).
Adverse Drug Reactions (ADRs) are common causes of hospitalization and lead to large costs
to society. There are two main financial burdens due to illnesses caused by ADRs: that of
treating and that of avoiding them [12]. The occurrence of serious and fatal ADRs has been
extensively studied in hospitalized patients and a meta-analysis of prospective studies in
approximately forty hospitals in the United States of America (USA) suggests that 6-7% of
hospitalized patients suffer from serious ADRs and 0.32% of patients develop fatal ADRs [13].
This results in approximately 100,000 deaths annually in the U.S. and an annual cost of over a
hundred billion dollars to the society due to prolonged hospitalization and reduced produc‐
tivity [3, 13]. Furthermore, it has been estimated that ADRs are responsible for up to 7% of all
admissions in hospitals in the United Kindown (UK) and 13% in medical clinics in Sweden [3],
which shows the magnitude of this problem in the context of chemotherapy and drug
development. Additionally, in France, a 10-year study in the Liver Unit of Hôpital Beaujon in
Paris showed that among all patients hospitalized with acute hepatitis, 10% were due to
adverse reaction to drugs and the prevalence of drug hepatotoxicity in patients older than fifty
years exceeded 40%. In Japan and other Eastern countries, drugs are responsible for about
10-20% of cases of fulminant hepatitis [14].
Liver injury is the most common ADR and the main complication during chemotherapy since
liver is the central organ for the biotransformation and excretion of most drugs and xenobiotics
[14-17]. There are basically six mechanisms involving primarily the hepatocyte injury. The
reactions of mono-oxygenase cytochrome P450 (CYP450) with certain drugs generate toxic
metabolites that bind to intracellular proteins, leading to calcium homeostasis pump dysfunc‐
tion with consequent disruption of actin fibers and cell lysis. Some drugs affect transport
proteins in the cell membrane interrupting the flow of bile and then causing cholestasis. Several
reactions involving CYP P450 can promote binding of the drug to the enzyme, with consequent
exposure of this complex on the cell surface for recognition by T cells and antibody production
as part of the autoimmune response. Finally, certain drugs may promote hepatic injury
mediated by programmed cell death (apoptosis) or being capable of inhibiting respiration and/
or mitochondrial beta-oxidation [17].
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Xenobiotics are usually lipophilic and this facilitates their transport in association with
lipoproteins in the blood stream and their penetration of lipid membranes and entrance into
organs. However, physicochemical properties of drug molecules difficult their removal from
the organism by biliary or renal excretion and therefore, these substances require enzymatic
conversion to water soluble compounds [1]. The xenobiotics metabolization, often through
multiple pathways, can generate metabolites that are more toxic than the substrate and through
their interaction with target macromolecules such as DNA, RNA, proteins and receptors,
generate the toxic effects. The organ affected is generally that reponsible for drug metaboli‐
zation or excretion of metabolites [1].
The enzyme systems responsible for the biotransformation of many drugs are located in the
endoplasmic reticulum of the liver (microsomal fraction). Such enzymes are also present in
the kidneys, lungs and gastrointestinal epithelium, although at a lower concentration [1]. The
metabolic modification in biotransformation usually takes place in two consecutive steps and
results in the loss of biological activity. Phase I reactions convert the xenobiotic into a metab‐
olite with higher polarity by oxidation, reduction or hydrolysis and generates a pharmaco‐
logically inactive or less active, or in the case of a pro-drug, more active molecule. This
metabolite is than either eliminated or go through Phase II reactions (so-called synthesis or
conjugation reactions), involving binding to a primary metabolite or endogenous substrate
such as glucuronate, sulfate, acetate, amino acids or glutathione (tripeptide). Such enzymatic
reactions include glucuronidation, methylation, sulfation, acetylation, conjugation with
glutathione and conjugation with glycine [1].
The risk for developing hepatotoxicity is associated both with genetic and acquired factors.
The acquired factors include: age, gender, nutritional habits, drug abuse, pregnancy and
extrahepatic disease. Genetic variations in isoenzymes involved in drug biotransformation can
result in abnormal reactions leading to toxic effects [14,17]. In the case of INH in particular,
advanced age is a risk factor for hepatotoxicity whereas deficiency in the ability of N-acetyla‐
tion represent a genetic risk factor for liver injury.
INH is administered orally and rapidly absorbed through the gastrointestinal tract passing
through the liver by the portal venous system before reaching the general circulation where is
metabolized by a process known as the first pass effect with reduction of its biodiponibility.
About 75% to 95% of the INH is excreted by the kidneys during the first 24 hours, mainly as
the metabolic forms acetyl-isoniazid and isonicotinic acid [1].
In the liver, INH is metabolized to acetylisoniazid by N-acetyltransferase 2 (NAT2), followed
by hydrolysis to acetylhydrazine and then oxidized by cytochrome P4502E1 (CYP2E1) to
hepatotoxic intermediates [18, 19]. These metabolites can destroy hepatocytes either by
interfering with cell homeostasis or by triggering immunologic reactions in which reactive
metabolites that are bound to hepatocyte plasma proteins may act as haptens [17]. The other
metabolic pathway to generate toxic metabolites is direct hydrolysis of INH to hydrazine, a
potent hepatotoxin. NAT2 is also responsible for converting acetylhydrazine to diacetylhy‐
drazine, a nontoxic component [18, 20, 21] (Figure 1). Glutathione S-transferase (GST), an
important phase II detoxification enzyme, is thought to play a protective role as an intracellular
free radical scavenger, which conjugates glutathione with toxic metabolites that are generated
Tuberculosis - Current Issues in Diagnosis and Management108
from CYP2E1 [22]. Sulphydryl conjugation facilitates the elimination of metabolites from the
body and reduces the toxic effect [23] (Figure 1).
Figure 1. Schematic representation of the INH metabolism. The major enzymes involved in this pathway are indicated
in boxes [20, 24].
In the last few years, an increasing number of studies have suggested that genetic polymor‐
phisms in NAT2, CYP2E1 and GST genes would be associated with susceptibility to drug-
induced hepatotoxicity during TB treatment. The present work focused in an overview of the
role of such polymorphisms in occurence of liver injury induced by anti-TB drugs, and by INH
in particular.
3. State of the art
3.1. N-acetyltransferase 2
NAT2, the main enzyme responsible for the metabolism and inactivation of INH in humans,
is a Phase II enzyme that catalyzes the transfer of the acetyl group from the cofactor acetyl
coenzyme A (acetyl-CoA) to the nitrogen terminal of the drug. Variations in activity of NAT2
were discovered over 50 years ago when observing interindividual differences in the metab‐
olism of INH and the level of drug-induced toxicity in TB patients. NAT2 is encoded by the
NAT2 gene and according family genetic studies, variability of NAT2 was directly related to
the emergence of different phenotypes of acetylation [25].
The molecular study of human N-acetyltransferases revealed the presence of three genetic loci,
two very homologous encoding the enzymes NAT1 and NAT2, and a third including the
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pseudogene pNAT (Figure 2). These loci are located on chromosome 8 between 170-360Kb at
8p22 [26]. The pNAT is a pseudogene containing a premature stop codon, and is not transcri‐
bed. NAT1 and NAT2 genes consist of 873 bp, are intronless, and encode proteins of 34 kDa.
Protein sequence homology between both enzymes is 81% while that between their respective
genes is 87%. Both enzymes have N-acetylation, O-acetylation and NO-transfer in different
xenobiotics and carcinogens but differ considerably in their tissue distribution and expression
levels during embryonic development [26-28].
Both NAT1 and NAT2 are polymorphic genes and SNPs in their coding region can alter the
enzymatic activity [29, 30] and are the basis of the three major genetically determined pheno‐
types, being rapid, intermediate and slow acetylators, which are inherited as a codominant
trait [31, 32]. The reference NAT2*4 allele (without mutations / wild-type) and 66 variants were
identified and classified in human populations depending on the combination of up to four
SNPs present throughout the NAT2 coding region [33]. So far, over 30 SNPs have been
identified in this region, including several rare mutations described in different populations
[34]. Among these, the seven most frequent are the 191 G>A (R64Q), 282 C>T (silent), 341 T>C
(I114T), 481 C>T (silent), 590 G>A (R197Q), 803 A>G (K268R) and 857 G>A (G286T) SNPs
identified in different human populations [35]. NAT2 alleles containing the 191G>A, 341T>C,
590G>A or 857G>A SNPs are associated with slow acetylator NAT2 alleles [33].
Figure 2. Schematic representation of NAT genes on human chromosome 8p22. Distribution of the seven most com‐
mon SNPs in NAT2. D8S21 represents a polymorphic marker situated in the NAT2 locus [26, 36].
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Presence of different SNPs in NAT2 can be easily determined by genotyping procedures such
as PCR-RFLP [37], allele specific PCR [38] or direct sequencing [39]. To achieve the NAT2
genotype of each individual and predict the phenotype, the haplotype of both chromosomes
is usually reconstructed using the statistic software (PHASEv2.1.1[40, 41]). Using haplotype
data, many studies have reported the frequencies of the different acetylation profiles among
ethnically different populations showing the high diversity around the world. In Asians and
Ameridians, the fast acetylator phenotype is more frequent [42-44] whereas in Euro-descend‐
ants slow acetylators account for 50% of the study population [37,45]. The molecular basis for
such discrepancy is that the most common NAT2 allele in Euro-descendants is very rare in
Asians and may represent a different selective advantage within the gene pools of these
separate populations. Description of new alleles of NAT2 is still ocurring in recent studies [34].
In an attempt to establish an association between acetylation profiles and development of
disease, cohort or case-control studies have been performed using of genotyping and pheno‐
typing tools. Evidence was found for an association between the slow acetylator predicted
phenotype and developing urinary bladder cancer, while rapid acetylators seem more
susceptible to development of colon cancer. For a review, see [27, 46].
For many years, INH has been considered the main cause of hepatotoxicity during TB
treatment and association studies between the acetylation phenotypes and susceptibility to
liver-related ADRs have been performed. Two early studies conducted in oriental populations
investigated the association of the acetylator phenotype with INH induced hepatotoxicity and
observed an increased risk of developing hepatotoxicity by INH among the slow acetilators
[47, 48]. This observation was confirmed in several other studies performed in different
populations [49-52].
Several studies reported the absence of a relationship between acetylation status and hepato‐
toxicity during TB treatment [53-55] but some, suggested the rapid acetylators as more
susceptible to side effects [55, 56]. Reasons for these different findings range from genotyping
methods to ethnicity. In some studies, NAT2 acetylation phenotypes were determined by an
enzymatic method leading to possible misclassification of the acetylation status [53, 56, 57].
Indeed, it is difficult to compare the accuracy of different NAT phenotyping methods or
different cut-off points using the same phenotyping method. In addition, for genotyping,
investigators sometimes select a small number of SNPs to define the acetylation status [54,
55]. Since the frequencies of NAT2 alleles are different among worldwide populations and new
alleles are been identified in some countries, investigators need to characterize such alleles in
their own study population in order to choose appropriate SNPs for genotyping and classify
the acetylation status of individuals, otherwise overestimation of slow acetylators may be
obtained, contributing to a spurious results in the association study.
Recently, a study with an admixed population showed that NAT2 is a genetic factor for
predisposition to anti-TB drug-induced hepatitis. In this case, NAT2 genes were well charac‐
terized by direct sequencing and their genotypes achieved by haplotype reconstruction using
the PHASE software. In addition, functional unknown genotypes were disconsidered and
others confounding variables for hepatotocixity were taken into account. The incidence of
elevated levels of serum transaminases was significantly higher in slow acetylators than those
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of the rapid/intermediate type. These results corroborate with the current hypothesis that the
acetylator status may be a risk factor for the hepatic side effects of isoniazid [58].
Finally, a meta-analysis was conducted to solve the problem of inadequate statistical power
and controversial results based on accumulated data with small sample size [59]. Data from
14 studies performed between 2000 and 2011 were pooled and showed that TB patients with
a slow acetylator genotype had a higher risk of anti-tuberculosis drug induced hepatotocixity
than patients with rapid or intermediate acetylation (p < 0.001). Moreover, subgroup analyses
indicate that both Asians and non-Asians slow acetylators develop anti-tuberculosis drug
induced hepatotocixity more frequently. Additionally, there were statistically significant
associations between NAT2*5/*7, NAT2*6/*6, NAT2*6/*7 and NAT2*7/*7 and the risk of anti-
TB drug induced hepatotocixity [59].
As a final consideration, NAT acetylates more slowly not only isoniazid but also acetylhydra‐
zine, the immediate precursor of toxic intermediates, to the harmless diacetylhydrazine [60,
61]. This protective acetylation is further suppressed by INH competition. Therefore, slow
acetylators may be prone to higher accumulation rates of INH toxic metabolites. Another
important route to generate toxic intermediates is the direct hydrolysis of unacetylated INH
[62], producing hydrazine that also induces hepatic injury [62, 63]. Pharmacokinetic studies
showed that the serum concentration of hydrazine was significantly higher in slow acetylators
than in rapid acetylators, probably due to the high INH concentration. The high amount of
INH disposed of through this pathway is likely to lead to enhanced hydrolysis to hydrazine,
since the rate of metabolic conversion of INH to acetylisoniazid is lower in slow than in rapid
acetylators [64, 65]. All of these drug-disposal processes may support the finding that slow
acetylators are prone to INH-induced hepatitis. We therefore conclude that screening of
patients for the NAT2 genetic polymorphisms can prove clinically useful for the prediction
and prevention of anti-tuberculosis drug induced hepatotoxicity.
3.2. CYP450
Cytochromes P450 (CYP450) are hemoproteins and form the most important enzymatic group
for Phase I biotransformation. The main activity of isozymes of CYP450 system is oxidation
and they are located in the smooth endoplasmic reticulum, mainly in liver cells. However,
these mono-oxygenases are also localized in the intestine, pancreas, brain, lung, kidney, bone
marrow, skin, ovary and testicles [66]. The CYP450 proteins are clustered into families and
subfamilies according to the similarity between the amino acid sequences: where family
members have ≥ 40% identity in amino acid sequence, members of the same subfamily share
≥ 55% identity [67].
The  CYP450s  are  responsible  for  the  metabolization  of  several  endogenous  substrates
and the synthesis of hydrophobic lipids such as cholesterol, steroid hormones, bile acids
and  fatty  acids.  Moreover,  some  enzymes  of  P450  complex  metabolize  exogenous  sub‐
stances including drugs, environmental chemicals and pollutants as well as products de‐
rived from plants. The metabolism of exogenous substances by CYP450 usually results in
detoxification  of  the  xenobiotic;  however,  the  reactions  triggered  by  such  enzymes  can
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lead to generation of toxic metabolites that contribute to the increased risk of developing
cancers and other toxic effects [68].
The complete sequencing of the human genome revealed the presence of about 115 genes of
CYP450, including 57 active genes and 58 pseudogenes [67]. They belong to families 1-3 and
are responsible for 70-80% of Phase I-dependent metabolism of clinically used drugs. Other
families of CYPs are involved in metabolism of endogenous components [66]. The CYP2
constitutes the largest family of isoenzymes and comprises one third of all human CYPs. Genes
encoding these enzymes are polymorphic and the frequency distribution of allelic variants in
different ethnic groups differs. Overall, four phenotypes based on genotypes can be identified:
(i) poor metabolizers who present low enzymatic activity, (ii) intermediate metabolizers,
usually heterozygous for a defective allele, (iii) rapid metabolizers, who have two normal
alleles and (iv) ultrarapid metabolizers, who have several gene copies [69].
The enzyme CYP2E1 is expressed mainly in the liver but can be found in other organs such as
kidney, gastrointestinal tract and brain and involved in oxidation of substrates such as ethanol
and the metabolism of many drugs and pre-carcinogens. Besides ethanol, CYP2E1 can be
induced by various drugs such as INH but also by hydrocarbons, benzene, chloroform and
various organic solvents [70].
The activity of CYP2E1 is also modulated by polymorphisms in several locations of its gene
and more activity of this enzyme may increase the synthesis of hepatotoxins. Two polymor‐
phisms upstream of the CYP2E1 transcriptional start site are characterized by Pst I and Rsa I
digestion and appear to be in complete linkage disequilibrium (Figure 3). These two poly‐
morphisms are located in a putative HNF-q binding site and thus may play a role in the
regulation of CYP2E1 transcription and subsequent protein expression [71]. Genotypes of
CYP2E1 are classified as being *1A/*1A, *1A/*5 or *5/*5 by Rsa I based restriction analysis. The
polymorphism detectable by Dra I (7632 T>A) is located in intron 6 and characterizes the allelic
variant CYP2E1*6. The other polymorphism is an insertion/deletion of 96 bp (CYP2E1*1D and
*1C alleles) that regulates the expression of the gene [72]. Some studies have shown that allelic
variants CYP2E1 *5, *6 and *1D would increase enzyme activity [71, 73]. However, other
authors did not confirm any relationship with these polymorphisms with CYP2E1 activity [74].
Figure 3. Polymorphic and corresponding restriction enzyme cutting sites at CYP2E1 [24].
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Several studies have described the involvement of polymorphisms in CYP2E1 in cancer
development but results are controversial. The studies showed that the frequency of SNP -1053
C>T in the promoter region varies significantly in different ethnic groups. The mutant allele
is present with a frequency of 2-8% in Euro-descendants but varies in Asia from 25 to 36% [75].
In 2003, Huang and coworkers showed an association of the wild-type genotype *1A/*1A
with risk of developing liver damage induced by isoniazid in adult TB patients,  regard‐
less of their profile of acetylation (OR 2.52;  95% CI 1.26 to 5.05) [76].  Later,  Vuilleumier
and colleagues showed association between this CYP and isoniazid-induced hepatotoxici‐
ty,  without  hepatitis,  during  chemoprophylaxis  for  TB  (OR  3.4;  95%  CI  1.1  to  12;  p  =
0.02).  The  risk  of  having  high  levels  of  liver  enzymes  was  3.4-fold  higher  when  com‐
pared with all  other CYP2E1  genotypes [55].  Another study on Indian children with TB
showed  association  between  risk  of  hepatotoxicity  and  polymorphisms  in  CYP2E1,  de‐
spite of low sample size [77].  However,  a study with on a Korean population found no
relationship  between  hepatic  adverse  effects  with  genotype  *1A/*1A  of  CYP2E1  during
anti-TB treatment [51].  Lack of  association between this  CYP and antituberculosis  drug-
induced  liver  injury  was  also  observed  in  Brazil  [58].  The  discrepancy  of  these  results
may be due to differences in the frequencies of CYP2E1*1A  and CYP2E1*5  alleles among
the populations and the different criteria to define hepatotoxicity used.
Finally, CYP2E1 converts acetyl hydrazine into hepatotoxins like acetyldiazene, ketene and
acetylonium ion. The reaction of acetyl hydrazine (at high levels) with CYP2E1 leads to
covalent binding of these secondary metabolites with intracellular proteins (Figure 1). As a
consequence, intracellular changes occur resulting in loss of ionic gradients and decrease of
ATP levels and consequent disruption of actin followed by cell lysis. Further studies in
different populations and with a larger sample size are needed to determine the true influence
of CYP2E1 gene polymorphisms on the occurrence of liver injury during treatment for TB.
3.3. Glutathione S-transferases
Glutathione S-transferases constitute a superfamily of multifunctional ubiquitous enzymes
that play an important role in cellular detoxification by protecting macromolecules against
reactive electrophilic attack. The GSTs are Phase II enzymes that catalyze the nucleophilic
attack of glutathione (GSH) into components that contain an electrophilic carbon, nitrogen or
sulfur atom. The combination of the GSH with these compounds often leads to formation of
less reactive and more water soluble products, more easily excreted by the body [23, 78].
Glutathione transferases are of great interest to pharmacologists and toxicologists, since they
are drug targets for the treatment of asthma and cancer, in addition to metabolize drugs,
insecticides, herbicides, carcinogens and products of oxidative stress. Polymorphisms in GST
genes are often correlated with susceptibility to various cancers, as well as alcoholic liver
disease [23, 78-81].
In humans, eight gene families of soluble (or cytosolic) GSTs have been described: alpha (α)
located on chromosome 6, mu (µ) on chromosome 1, theta (θ) on chromosome 22, pi (π) on
chromosome 11; zeta (ζ) on chromosome 14, sigma (σ) on chromosome 4; kappa (κ) (chromo‐
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somal location not given) and omega (Ω) on chromosome 10 [80]. This classification is based
on amino acid sequences, substrate specificity, chemical affinity, protein structure and enzyme
kinetics. These enzymes are highly expressed in the liver and constitute up to 4% of total
soluble proteins but can be seen in several other tissues [82]. GSTs have an overlap of specific
substrates and the deficiency in one isoform can be compensated by other isoforms. Gluta‐
thione S-transferase mu (GSTM), glutathione S-transferase theta (GSTT) and glutathione S-
transferase Pi (GSTP) have been the most studied isoform [83-88].
The subfamily GST mu is encoded by five genes arranged in tandem (5_-GSTM4-GSTM2-
GSTM1-GSTM5-GSTM3-_3), forming a 100 kb gene cluster on chromosome 1p13.3 (Figure 4).
Polymorphisms have been identified and clinical consequences of genotypes resulting from
combinations of alleles GSTM1*0, GSTM1*A, and GSTM1*B have been widely investigated [78,
81, 89, 90]. Individuals who possess the homozygous null for GSTM1 (GSTM1*0/GSTM1*0) do
not express this protein. Thus, the absence of this gene can cause an increased accumulation
of reactive metabolites in the body, increasing the interaction with cellular macromolecules
and tumor initiation process. GSTM1*A and GSTM1*B differ in only one base in exon 7 and
encode monomers that form active dimers. The catalytic activity of these enzymes are very
similar [91].
The GSTM1 gene is flanked by two almost identical 4.2-kb regions. GSTM1*0 originates from
homologous recombination between the two repeat regions which results in a 16 Kb deletion
containing the entire gene GSTM1 (Figure 4). GSTM1 is precisely excised leaving the adjacent
GSTM2 and GSTM5 genes intact [78]. In a study of liver specimens of 168 autopsied Japanese
subjects, observed was that the GSTM1*0 null allele was more frequent in livers with hepatitis
and hepatocellular carcinoma compared to control livers [92].
Figure 4. Structural localization of 100 kb gene cluster encoding the GST mu subfamily (chromosome 1p13.3). The
figure indicates the homologous recombination event that can happen causing the null allele (GSTM1*0 - no GSTM1).
Figure adapted from [78].
The subfamily GST theta consists of two genes, GSTT1 and GSTT2, located on chromosome
22q11.2 and separated by approximately 50 Kb (Figure 5). Analysis of the 119 Kb portion
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containing these genes revealed two regions flanking GSTT1, HA3 and HA5, with more than
90% homology. HA3 and HA5 contain two identical 403-bp repeats and the occurence of
GSTT1*0 allele is probably caused by homologous recombination between the two regions [78].
In humans, GSTT1 is also expressed in erythrocytes and probably plays a global role in early
detoxification of xenobiotics and carcinogens.
Figure 5. Structural localization of gene cluster encoding the GST subfamily theta (chromosome 22q11.2). The GSTT1
null allele (GSTT1*0) arises by homologous recombination of the left and right 403-bp repeats, which results in a 54-
kb deletion containing the entire GSTT1 gene. Figure adapted from [78].
Deficiencies in the GST activity due to the null genotypes of GSTM1 and GSTT1 may modulate
susceptibility to the development of hepatotoxicity induced by drugs and xenobiotics.
Furthermore, it was observed that the frequencies of GSTT1*0 and GSTM1*0 alleles vary within
different ethnic groups [78, 82]. Liver injury induced by INH has been associated with the
depletion of glutathione content and reduction of GST activity in an animal model for
hepatotoxicity by anti-TB drugs [22].
In 2001, Roy and colleagues demonstrated that individuals, homozygous for the null GSTM1,
had a relative risk of 2.12 for developing hepatotoxicity induced by anti-TB drugs. However,
these authors found no association of the GSTT1 null genotype with this side effects [54].
Similarly, another study in the Thai population found that only the GSTM1 null genotype
increases the risk of liver injury (OR 2.23, 95% CI 1.07 to 4.67) [93]. The opposite was observed
by Leiro and colleagues: individuals with the GSTT1 null genotype had an increased risk of
developing hepatotoxicity induced by anti-TB drugs and no significant association was
observed between GSTM1*0/*0 genotype and liver injury [94]. These studies suggest a
protective effect of glutathione S-transferases to the hepatotoxic effects of isoniazid.
On the other hand, recent studies in different population showed no relationship between
GSTM1*0/*0 or GSTT1*0/*0 genotypes and liver injury during anti-TB treatment [58, 95, 96].
In a population-based prospective antituberculosis treatment coort in China, a more robust
case-control study was conducted and there was no statistically significant association between
null genotypes and hepatotoxicity induced by anti-TB drugs [97].
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These controversal results may be due to the small sample size in many studies and the
different frequencies of the null genotypes. New populations should be evaluated with large
sample size to see which of these polymorphisms can be used as genetic markers for the risk
of side effects during anti-TB treatment.
4. Conclusion
The concept of personalized medicine is not really new, but it has been receiving increasing
attention in recent years for improval of drug regulation and medical guidelines. There is
considerable interindividual variability in metabolism, partly due to human differences on a
genetic level. Genetic polymorphisms in drug-metabolizing enzymes can affect enzyme
activity and may cause differences in treatment response or drug toxicity, for example, due to
an increased formation of reactive metabolites. Such polymorphisms may explain differences
in incidence of anti-TB drugs induced hepatotoxicity between different populations.
Genotyping cannot completely predict the phenotype on an individual level because of to the
additional contribution of epigenetic, endogenous and environmental factors. However,
pharmacogenetics is able to add important information in many cases where therapeutic drug
scheme is inappropriate or not sufficient. Nowadays, we can cite three examples of personal‐
ized medicine application in clinical practice, (i) AIDS treatment (abavir / skin hypersensitiv‐
ity / HLA-B*5701), (ii) anticoagulation (warfarin / bleeding / CYP2C9) and (iii) treatment of
acute lymphoblastic leukemia (azathioprine / treatment resistence / TPMT) [98].
Although limited information exists regarding isoniazid concentrations that cause toxic
reactions, it has been proposed to adjust isoniazid dosage depending on individuals acetylator
status: a lower dosage for slow acetylators to reduce the risk of liver injury and a higher
isoniazid dosage for fast acetylators to increase the early bactericidal activity and thereby lower
the probability of treatment failure [50]. However, more robust clinical prospective studies are
needed to evaluate the real contribution of these different polyporphirms in the occurence of
liver side effects during anti-TB treatment. Future studies should include larger sample size,
different ethnic population, simultaneous analysis of different genetic markers, different
degrees of liver injury and consideration of possible confounding factors.
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